WhiteLab Genomics

Throwback Thursday! We had a fantastic time at the Schrödinger User Group meeting in Stockholm! Our Structural Biology team enjoyed several days of learning about the latest Schrödinger solution advancements that we implement to revolutionize gene therapy. Thank you Schrödinger for a great experience and to all the speakers for their engaging talks and discussions. Special thanks to Valentina Cantatore and Katalin Phimister for their dedicated time. Ft: Dylan SERILLON (PharmD, PhD) Camille Alliot, Bryan Dafniet, Juliette Maes, Claire Colas

Have you been following our Q&A series? If you'd like to see something covered, comment below!

Throwback Thursday to our team summer outing on the Seine! What an incredible night with beautiful views, great food, drinks, laughter, and more. 🎉

“You start testing it and looking to see where things show the most positive signal and use that as your north star.” In addition to testing,Nicole K. Paulk, PhD says, Siren Biotechnology relies on artificial intelligence to predict the most-promising indication. The company is collaborating with WhiteLab Genomics and utilizing its AI-powered platform to accelerate the identification of new indications." Great article on our partners Siren Biotechnology by Tyler Menichiello at Cell & Gene:

"Despite the impressive number of drug targets discovered so far, it is estimated that – given the current level of understanding the genotype-phenotype relationships and available modalities – only around 5% to 15% of those targets are druggable, i.e., able to be therapeutically modulated by medicines.  AI could help bridge this gap by analyzing vast genomic databases and producing new biological insights into molecular pathways or genetic links. This can lead to the discovery of new or better targets for drug development. AstraZeneca, for example, uses large-scale gene editing screening to modify genes in genomes and search for phenotypic outcomes that mimic desired drug effects on cells, tissues, organs, and the entire body."

WhiteLab Wednesdays! We are thankful to have team members like Oscar de Felice whose knowledge, expertise, and passion contribute immensely to our team. Check out what Oscar had to say about his work at WhiteLab and what makes working here unique!

Looking for your next career adventure? We are on the search for a Computational Structural Biologist! Here’s how you’ll make an impact… 💥 You’ll design and execute new modeling tasks for WhiteLab Genomics’ projects, including contributing to the development of our cell & gene therapy platform by using molecular modeling, protein design and machine and/or deep learning algorithms applied to structural biology. 💥 You’ll participate in various scientific projects related to gene therapies, while working on R&D development. 💥 You’ll collaborate with our engineers to conduct rigorous data analysis and statistical modeling, ensuring clear and efficient communication of results internally and externally. 💥 You’ll stay up-to-date on the latest developments in both structural biology and AI applied to structural biology and relevant applications. 💥 You’ll monitor emerging technologies and trends, assessing their viability and potential integration into our platform and operations. ....and more! https://lnkd.in/enGQj8Kh

"WhiteLab Wednesdays"! Check out some behind the scenes photos of our team building day last month. It's always fun getting to know everyone outside the office, learn more about who they are, share some laughs, discover some hidden talents, and more! Stay tuned for more! Ft: Oscar de Felice Dylan SERILLON (PharmD, PhD) Camille Alliot Fanny Goretta Xi LIU Monchida Likitphatham

We love watching other innovators in our space make headway! Terray Therapeutics progress highlights a broader trend in biotech, where AI-driven solutions are making significant strides in identifying new drug targets and optimizing molecular design. As AI continues to evolve, its potential to revolutionize healthcare and improve patient outcomes grows exponentially. Great read by Steve Lohr at The New York Times: Ft: Eli Berlin Jacob Berlin, PhD Kathleen Elison Narbe Mardirossian

Check out our Global Head of BD&L Timothé CYNOBER (Pharm D.) and Structural Biologist, Camille Alliot's interview with Viva Technology!